Manufacture and market a wide range of pharmaceuticals globally. Develop innovative therapies for oncology, urology, and transplant medicine. Now — the numbers.
This is an established company with proven profits.
Average growth of 15% a year over the last 4 years. Every year shown ended in profit.
If every debt were paid off today, $233.0M would still be left in the vault — a solid cushion for hard times.
The market pays 13× for every dollar of annual profit — cheap, which is either an opportunity or a warning.
No analyst target is on record for this company.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Trading Liquidity: The shares change hands too rarely for smooth trading.
The stock trades 19% below its peak. The market has trimmed its expectations for the company.
Over the last 4 years, sales grew about 15% a year on average.
There is $1.8B in the vault; even if every debt were paid off, $233.0M would remain.
It met or beat analyst expectations in 7 of the last 8 quarters — consistency is a promise kept.
Getting in and out without moving the price could prove difficult. Council score: 2/10.
Since the drop from its peak, buyer appetite hasn’t come back. Council score: 3/10.
Against everything we grade, ALPMY lands somewhere in the middle. The grade moves as the numbers move.
The takeaway: ALPMY is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.
Not covered, because the filings we hold do not carry it: the revenue breakdown.